PDF(Pubmed)
Abstract：
UNASSIGNED: To investigate the clinical effects of TP-based hyperthermic intraperitoneal chemotherapy (HIPEC) on the levels of antigen cluster protein 133 (CD133) and human epididymal secretory protein 4 (HE4) in patients with advanced epithelial ovarian cancer (EOC).
UNASSIGNED: A total of 104 patients with advanced EOC hospitalized in Affiliated Hospital of Hebei Engineering University from April 2015 to December 2018 were assigned to two groups using a random number table. A control group (n =52) treated by the conventional postoperative TP regimen and an observation group (n =52) receiving HIPEC in addition to the conventional postoperative TP regimen. CD133 and HE4 expression in serum, overall response rate (ORR), long-term efficacy, and incidence of drug toxicity were measured for comparative analysis.
UNASSIGNED: The serum levels of CD133 and HE4 expression in the observation group were lower than in the control group (P < 0.005, respectively); the observation group surpassed the control group in ORR, 2-year survival, and progression-free survival (PFS) (P < 0.005, respectively); however, the two groups had no statistically significant difference in the incidence of drug toxicity (P > 0.05).
UNASSIGNED: TP-based HIPEC can effectively inhibit CD133 and HE4 expression in advanced EOC, which thereby improves the clinical efficacy and encourages longer survival.
UNASSIGNED: A total of 104 patients with advanced EOC hospitalized in Affiliated Hospital of Hebei Engineering University from April 2015 to December 2018 were assigned to two groups using a random number table. A control group (n =52) treated by the conventional postoperative TP regimen and an observation group (n =52) receiving HIPEC in addition to the conventional postoperative TP regimen. CD133 and HE4 expression in serum, overall response rate (ORR), long-term efficacy, and incidence of drug toxicity were measured for comparative analysis.
UNASSIGNED: The serum levels of CD133 and HE4 expression in the observation group were lower than in the control group (P < 0.005, respectively); the observation group surpassed the control group in ORR, 2-year survival, and progression-free survival (PFS) (P < 0.005, respectively); however, the two groups had no statistically significant difference in the incidence of drug toxicity (P > 0.05).
UNASSIGNED: TP-based HIPEC can effectively inhibit CD133 and HE4 expression in advanced EOC, which thereby improves the clinical efficacy and encourages longer survival.
摘要：
■探讨以TP为基础的腹腔热化疗(HIPEC)对晚期上皮性卵巢癌(EOC)患者血清抗原簇蛋白133(CD133)和人附睾分泌蛋白4(HE4)水平的影响。
■将2015年4月至2018年12月河北工程大学附属医院收治的104例晚期卵巢上皮癌患者采用随机数字表法分为两组。对照组(n=52)采用常规术后TP方案治疗,观察组(n=52)除常规术后TP方案外还接受HIPEC治疗。CD133和HE4在血清中的表达，总反应率（ORR），长期疗效，和药物毒性发生率进行比较分析。
■观察组血清CD133和HE4表达水平低于对照组(P<0.005);观察组ORR优于对照组,2年生存率,和无进展生存期（PFS）（分别为P<0.005）；然而，两组药物毒性发生率差异无统计学意义(P>0.05)。
■基于TP的HIPEC可有效抑制晚期EOC中CD133和HE4的表达，从而提高了临床疗效并鼓励更长的生存期。
■将2015年4月至2018年12月河北工程大学附属医院收治的104例晚期卵巢上皮癌患者采用随机数字表法分为两组。对照组(n=52)采用常规术后TP方案治疗,观察组(n=52)除常规术后TP方案外还接受HIPEC治疗。CD133和HE4在血清中的表达，总反应率（ORR），长期疗效，和药物毒性发生率进行比较分析。
■观察组血清CD133和HE4表达水平低于对照组(P<0.005);观察组ORR优于对照组,2年生存率,和无进展生存期（PFS）（分别为P<0.005）；然而，两组药物毒性发生率差异无统计学意义(P>0.05)。
■基于TP的HIPEC可有效抑制晚期EOC中CD133和HE4的表达，从而提高了临床疗效并鼓励更长的生存期。
